Sesen Bio, Inc.
SESN · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.22 | 0.00 |
| FCF Yield | -230.32% | 409.56% | -927.14% | -386.54% |
| EV / EBITDA | 0.00 | 2.09 | 18.15 | 2.11 |
| Quality | ||||
| ROIC | 0.00% | -13.71% | -0.15% | -21.50% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.99 | -1.25 | 204.99 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 52.69% | – | – |
| Free Cash Flow Growth | 0.00% | 136.14% | -123.32% | 18.09% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 2.21 | 19.02 | 2.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 7.53 | 336.80 | 0.00 |